Nature Medicine Publication of ASPEN-06 Ph 2 Data Demonstrates Strong Responses and Durable Clinical Benefit with Evorpacept in HER2-Positive Gastric Cancer October 1, 2026
MAA submitted to EMA for Lirafugratinib for Advanced/Metastatic Cholangiocarcinoma (CCA) Harboring FGFR2 Fusions or Rearrangements September 22, 2026
US FDA Breakthrough Therapy Designation for RASONQUE™ (daraxonrasib) + Chemo for 1L Metastatic Pancreatic Cancer September 22, 2026
FDA approves BEXLUTRY lutetium Lu 177 dotatate injection for adults with SSTR-positive GEP-NETs September 22, 2026
HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy September 9, 2026
AIM ImmunoTech Secures Broad US Patent for Rintatolimod (Ampligen®) Used in Combination with Keytruda, Expanding Oncology IP Protection for Ampligen Through 2039 September 9, 2026
DSMB recommends termination of Ph 2 trial of adjuvant BNT122-01 in patients with circulating tumor DNA-positive, surgically resected Stage II/III CRC September 2, 2026
Ziihera® (zanidatamab-hrii) + Chemo Demonstrates Statistically Significant OS Benefit vs Trastuzumab + Chemo in 1L HER2+ Advanced GEA September 2, 2026
DB-1317 Granted FDA Fast Track Designation for Treatment of Advanced Pancreatic Ductal Adenocarcinoma September 2, 2026
Emmaus Life Sciences Announces Agreement for Evaluation of L-glutamine for Pancreatic Cancer September 2, 2026
First Patient Dosed in Ph 3 Study of ASP2138 in CLDN18.2+ve and HER2-neg locally advanced unresectable or metastatic GEJ adenocarcinoma September 2, 2026
Updated NEST Ph 2 Publication Reporting Deep Pathologic Responses and No Observed Recurrences with Neoadjuvant BOT+BAL in Resectable Colon Cancer September 2, 2026
Ivonescimab + Chemo Demonstrates Statistically Significant OS Benefit vs Durvalumab + Chemo in 1L Advanced BTC in China September 2, 2026
NMPA Approves ATLED® (Fanregratinib) for the Treatment of Patients with FGFR2-Fusion/Rearrangement Intrahepatic Cholangiocarcinoma September 2, 2026
SYS6090 (JMT108) Granted Fast Track Designation by FDA for Treatment of Patients with MSS/pMMR mCRC September 2, 2026
